HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

<p>Abstract</p> <p>Background</p> <p>The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is low, prompting interest in targeted molecular therapies. We investigated HER2 expression and amplification, and the potential for trastuzumab therapy in th...

Full description

Bibliographic Details
Main Authors: Swenerton Kenneth D, Kalloger Steve E, Köbel Martin, Adamiak Anna, Ronnett Bridgett M, Vang Russell, Wiegand Kimberly C, McAlpine Jessica N, Huntsman David G, Gilks C, Miller Dianne M
Format: Article
Language:English
Published: BMC 2009-12-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/9/433

Internet

http://www.biomedcentral.com/1471-2407/9/433

Similar Items